

Mauro Krampera

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5879554/mauro-krampera-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

141
papers

8,717
citations

42
h-index

93
g-index

144
ext. papers

10,364
ext. citations

5.1
avg. IF

5.9
L-index

#	Paper	IF	Citations
141	The transcriptional profile of adipose-derived stromal cells (ASC) mirrors the whitening of adipose tissue with age.. <i>European Journal of Cell Biology</i> , 2022 , 101, 151206	6.1	0
140	COVID-19 (SARS-CoV-2 infection) in lymphoma patients: A review.. <i>World Journal of Virology</i> , 2021 , 10, 312-325	6.9	4
139	Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. <i>Cell Stem Cell</i> , 2021 , 28, 1708-1725	18	12
138	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. <i>Blood Advances</i> , 2021 ,	7.8	4
137	Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools. <i>Targeted Oncology</i> , 2021 , 16, 823-838	5	0
136	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. <i>Hematological Oncology</i> , 2021 , 39, 409-418	1.3	3
135	Familial occurrence of systemic and cutaneous mastocytosis in an adult multicentre series. <i>British Journal of Haematology</i> , 2021 , 193, 845-848	4.5	1
134	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. <i>Cancer</i> , 2021 , 127, 2657-2665	6.4	7
133	Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition. <i>Cytotherapy</i> , 2021 , 23, 368-372	4.8	8
132	Interferon regulatory factor 7 impairs cellular metabolism in aging adipose-derived stromal cells. <i>Journal of Cell Science</i> , 2021 , 134,	5.3	1
131	Consensus International Council for Commonality in Blood Banking Automation-International Society for Cell & Gene Therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. <i>Cytotherapy</i> , 2021 , 23, 1060-1063	4.8	3
130	Transfusion of blood products derived from SARS-CoV-2+ donors to patients with hematological malignancies. <i>Transfusion and Apheresis Science</i> , 2021 , 60, 103105	2.4	2
129	Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996. <i>American Journal of Hematology</i> , 2021 , 96, E334-E338	7.1	1
128	Efficacy of R-COMP in comparison to R-CHOP in patients with DLBCL: A systematic review and single-arm metanalysis. <i>Critical Reviews in Oncology/Hematology</i> , 2021 , 163, 103377	7	1
127	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021 , 35, 787-795	10.7	19
126	Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2021 , 192, 333-342	4.5	2
125	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. <i>British Journal of Haematology</i> , 2021 , 193, 356-368	4.5	8

124	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. <i>Blood Cancer Journal</i> , 2021 , 11, 4	7	16
123	COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies. <i>British Journal of Haematology</i> , 2021 , 195, 371-377	4.5	15
122	The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population. <i>Cancer Medicine</i> , 2021 , 10, 6310-6316	4.8	2
121	High-throughput analysis and functional interpretation of extracellular vesicle content in hematological malignancies. <i>Computational and Structural Biotechnology Journal</i> , 2020 , 18, 2670-2677	6.8	5
120	Cell-based therapies for coronavirus disease 2019: proper clinical investigations are essential. <i>Cytotherapy</i> , 2020 , 22, 602-605	4.8	23
119	Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome. <i>European Journal of Haematology</i> , 2020 , 105, 468-475	3.8	4
118	Functional dosing of mesenchymal stromal cell-derived extracellular vesicles for the prevention of acute graft-versus-host-disease. <i>Stem Cells</i> , 2020 , 38, 698-711	5.8	20
117	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data. <i>Hematological Oncology</i> , 2020 , 38, 372-380	1.3	7
116	Regulative Loop between Ectenin and Protein Tyrosine Receptor Type η in Chronic Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	8
115	BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC". <i>Blood</i> , 2020 , 136, 9-10	2.2	1
114	Efficacy of Idelalisib and Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Treated Outside of Clinical Trial. a Report of the Gimema Group. <i>Blood</i> , 2020 , 136, 23-25	2.2	
113	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. <i>Blood</i> , 2020 , 136, 17-18	2.2	0
112	Prospective Evaluation of a Continuation Therapy with Midostaurin in Adult Patients with Core-Binding Factor Leukemia and Integrated Genetic Analysis: A Multi Center Phase II Study. Preliminary Results. <i>Blood</i> , 2020 , 136, 37-38	2.2	
111	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. <i>Blood</i> , 2020 , 136, 49-50	2.2	
110	Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study). <i>Blood</i> , 2020 , 136, 42-42	2.2	
109	First Line Treatment with Hydroxyurea in Patients with Polycythemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. <i>Blood</i> , 2020 , 136, 43-44	2.2	
108	Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice. <i>British Journal of Haematology</i> , 2020 , 189, 879-887	4.5	13
107	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. <i>Blood</i> , 2020 , 136, 43-44	2.2	2

106	Bendamustine plus rituximab: is it a BRIGHT idea?. <i>Chinese Clinical Oncology</i> , 2020 , 9, 22	2.3	
105	Emerging data supporting stromal cell therapeutic potential in cancer: reprogramming stromal cells of the tumor microenvironment for anti-cancer effects. <i>Cancer Biology and Medicine</i> , 2020 , 17, 828-841	5.2	2
104	Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. <i>HemaSphere</i> , 2020 , 4, e395	0.3	2
103	Is triple-positive serology for Epstein-Barr virus (VCA-IgG, VCA-IgM, EBNA-IgG) a specific feature of angioimmunoblastic T-cell lymphoma?. <i>Tumori</i> , 2020 , 106, 424-426	1.7	0
102	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020 , 126, 1243-1252	6.4	51
101	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice. <i>Cancers</i> , 2020 , 12,	6.6	4
100	Tumor Microenvironment Uses a Reversible Reprogramming of Mesenchymal Stromal Cells to Mediate Pro-tumorigenic Effects. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 545126	5.7	9
99	HS-5 and HS-27A Stromal Cell Lines to Study Bone Marrow Mesenchymal Stromal Cell-Mediated Support to Cancer Development. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 584232	5.7	3
98	Extracellular Vesicle-Dependent Communication Between Mesenchymal Stromal Cells and Immune Effector Cells. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 596079	5.7	12
97	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020 , 7, e737-e745	14.6	223
96	Small Molecule Inhibitors of Microenvironmental Wnt/ β Catenin Signaling Enhance the Chemosensitivity of Acute Myeloid Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	7
95	The Evolving Knowledge on T and NK Cells in Classic Hodgkin Lymphoma: Insights into Novel Subsets Populating the Immune Microenvironment. <i>Cancers</i> , 2020 , 12,	6.6	1
94	Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma. <i>Frontiers in Oncology</i> , 2020 , 10, 600025	5.3	4
93	The Role of Notch and Wnt Signaling in MSC Communication in Normal and Leukemic Bone Marrow Niche. <i>Frontiers in Cell and Developmental Biology</i> , 2020 , 8, 599276	5.7	6
92	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019 , 37, 418-423	1.3	2
91	Extracellular Vesicles Mediate Mesenchymal Stromal Cell-Dependent Regulation of B Cell PI3K-AKT Signaling Pathway and Actin Cytoskeleton. <i>Frontiers in Immunology</i> , 2019 , 10, 446	8.4	39
90	CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients. <i>Annals of Hematology</i> , 2019 , 98, 2339-2346	3	3
89	Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT) Mesenchymal Stromal Cell committee position statement on nomenclature. <i>Cytotherapy</i> , 2019 , 21, 1019-1024	4.8	220

88	Management of Chronic Myeloid Leukemia in Advanced Phase. <i>Frontiers in Oncology</i> , 2019 , 9, 1132	5.3	26
87	Prognostic Impact of t(4;11)(q21;q23)/KMT2A-AFF1-Positivity in 926 BCR-ABL1-Negative B-Lineage Acute Lymphoblastic Leukemia Patients Treated in Gimema Clinical Trials Since 1996. <i>Blood</i> , 2019 , 134, 1469-1469	2.2	
86	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. <i>Blood</i> , 2019 , 134, 4166-4166	2.2	
85	Comorbidities Reduce Response to Induction Treatment and Survival in Adults with Philadelphia-Negative Acute Lymphoblastic Leukemia. <i>Blood</i> , 2019 , 134, 2587-2587	2.2	
84	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019 , 134, 4184-4184	2.2	
83	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. <i>Blood</i> , 2019 , 134, 4174-4174	2.2	1
82	Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study. <i>Blood</i> , 2019 , 134, 5909-5909	2.2	
81	Notch Signaling Molecules as Prognostic Biomarkers for Acute Myeloid Leukemia. <i>Cancers</i> , 2019 , 11,	6.6	11
80	Inhibition of Notch Signaling Enhances Chemosensitivity in B-cell Precursor Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2019 , 79, 639-649	10.1	23
79	Role of mesenchymal stromal cell-derived extracellular vesicles in tumour microenvironment. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019 , 1871, 192-198	11.2	19
78	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018 , 132, 4277-4277	2.2	8
77	Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. <i>Oncotarget</i> , 2018 , 9, 14219-14227	3.3	7
76	Characterization of a new B-ALL cell line with constitutional defect of the Notch signaling pathway. <i>Oncotarget</i> , 2018 , 9, 18341-18350	3.3	8
75	MicroRNA signatures and Foxp3 cell count correlate with relapse occurrence in follicular lymphoma. <i>Oncotarget</i> , 2018 , 9, 19961-19979	3.3	10
74	MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. <i>Oncotarget</i> , 2018 , 9, 29753-29771	3.3	9
73	Prognostic Impact of Notch Signaling in Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018 , 132, 5242-5242	2.2	0
72	Presentation and Outcome of 199 Patients with 2016 Who Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. <i>Blood</i> , 2018 , 132, 3052-3052	2.2	
71	Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. <i>International Journal of Obesity</i> , 2018 , 42, 334-343	5.5	22

70	Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. <i>Leukemia Research</i> , 2018 , 74, 75-79	2.7	7
69	Primary sphenoid lymphoma: Focus on imaging. <i>Tumori</i> , 2018 , 104, NP42-NP45	1.7	1
68	Stem cells to restore insulin production and cure diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017 , 27, 583-600	4.5	19
67	Developmental pathways associated with cancer metastasis: Notch, Wnt, and Hedgehog. <i>Cancer Biology and Medicine</i> , 2017 , 14, 109-120	5.2	60
66	Mesenchymal stromal cells Proliferate in tumor microenvironment: involvement of signaling pathways. <i>Cancer Biology and Medicine</i> , 2017 , 14, 129-141	5.2	55
65	Mesenchymal Stem/Stromal Cell Trafficking and Homing 2017 , 169-191		
64	A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type β in chronic myeloid leukemia patients. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 129	22.4	15
63	Mesenchymal stromal cells (MSCs) induce ex vivo proliferation and erythroid commitment of cord blood haematopoietic stem cells (CB-CD34+ cells). <i>PLoS ONE</i> , 2017 , 12, e0172430	3.7	22
62	Identification of microRNAs implicated in the late differentiation stages of normal B cells suggests a central role for miRNA targets ZEB1 and TP53. <i>Oncotarget</i> , 2017 , 8, 11809-11826	3.3	11
61	Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy. <i>Oncotarget</i> , 2017 , 8, 86987-87001	3.3	13
60	International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. <i>Cytotherapy</i> , 2016 , 18, 151-9	4.8	278
59	Role of Wnt/ β Catenin Signalling in Acute Myeloid Leukemia (AML) Cell Response to Chemotherapy. <i>Blood</i> , 2016 , 128, 2753-2753	2.2	2
58	Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study. <i>Blood</i> , 2016 , 128, 5434-5434 ^{2,2}		
57	CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations. <i>Blood</i> , 2016 , 128, 3122-3122	2.2	
56	Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia. <i>Oncotarget</i> , 2016 , 7, 21713-27	3.3	54
55	Differential and transferable modulatory effects of mesenchymal stromal cell-derived extracellular vesicles on T, B and NK cell functions. <i>Scientific Reports</i> , 2016 , 6, 24120	4.9	168
54	In Vivo Effects of Mesenchymal Stromal Cells in Two Patients With Severe Acute Respiratory Distress Syndrome. <i>Stem Cells Translational Medicine</i> , 2015 , 4, 1199-213	6.9	90
53	Immunophenotypic analysis of hematopoiesis in patients suffering from Shwachman-Bodian-Diamond Syndrome. <i>European Journal of Haematology</i> , 2015 , 95, 308-15	3.8	6

52	Effects of a ceramic biomaterial on immune modulatory properties and differentiation potential of human mesenchymal stromal cells of different origin. <i>Tissue Engineering - Part A</i> , 2015 , 21, 767-81	3.9	15
51	Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. <i>Haematologica</i> , 2015 , 100, e299-301	6.6	9
50	Meninges harbor cells expressing neural precursor markers during development and adulthood. <i>Frontiers in Cellular Neuroscience</i> , 2015 , 9, 383	6.1	31
49	Injection molded polymeric micropatterns for bone regeneration study. <i>ACS Applied Materials & Interfaces</i> , 2015 , 7, 7273-81	9.5	13
48	Immune regulatory properties of CD117(pos) amniotic fluid stem cells vary according to gestational age. <i>Stem Cells and Development</i> , 2015 , 24, 132-43	4.4	40
47	Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. <i>British Journal of Cancer</i> , 2015 , 112, 1067-75	8.7	100
46	The challenge of defining mesenchymal stromal cell potency assays and their potential use as release criteria. <i>Cytotherapy</i> , 2015 , 17, 125-7	4.8	55
45	Signaling pathways in breast cancer: therapeutic targeting of the microenvironment. <i>Cellular Signalling</i> , 2014 , 26, 2843-56	4.9	60
44	Mesenchymal stem cell biodistribution, migration, and homing in vivo. <i>Stem Cells International</i> , 2014 , 2014, 292109	5	24
43	Comparative study of immune regulatory properties of stem cells derived from different tissues. <i>Stem Cells and Development</i> , 2013 , 22, 2990-3002	4.4	68
42	MSCs: science and trials. <i>Nature Medicine</i> , 2013 , 19, 812	50.5	38
41	Clinical-grade mesenchymal stromal cells produced under various good manufacturing practice processes differ in their immunomodulatory properties: standardization of immune quality controls. <i>Stem Cells and Development</i> , 2013 , 22, 1789-801	4.4	128
40	Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal. <i>Cytotherapy</i> , 2013 , 15, 1054-61	4.8	285
39	Comparison Between Bone Marrow Mesenchymal Stromal Cells (BM-MS) and Lung Mesenchymal Stromal Cells (Lung-MS) For Epithelial Regeneration. <i>Blood</i> , 2013 , 122, 5414-5414	2.2	2
38	Genomic Analysis Of Notch Mutations In a Case Of Alagille Syndrome With Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 4992-4992	2.2	0
37	Mesenchymal Stem Cell Isolation and Expansion Methodology 2012 , 23-33		
36	Comparison of epithelial differentiation and immune regulatory properties of mesenchymal stromal cells derived from human lung and bone marrow. <i>PLoS ONE</i> , 2012 , 7, e35639	3.7	59
35	VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type. <i>PLoS ONE</i> , 2012 , 7, e52811	3.7	3

34	Role of stromal cell-mediated Notch signaling in CLL resistance to chemotherapy. <i>Blood Cancer Journal</i> , 2012 , 2, e73	7	63
33	Neural stem cell niches in health and diseases. <i>Current Pharmaceutical Design</i> , 2012 , 18, 1755-83	3.3	65
32	Meninges: from protective membrane to stem cell niche. <i>American Journal of Stem Cells</i> , 2012 , 1, 92-105	2.4	59
31	Mesenchymal stem cells and autoimmune diseases. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 49-57	4.2	86
30	Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells. <i>Blood</i> , 2011 , 118, 380-9	2.2	90
29	Notch signaling in acute lymphoblastic leukemia: any role for stromal microenvironment?. <i>Blood</i> , 2011 , 118, 6506-14	2.2	33
28	Mesenchymal stromal cell licensing: a multistep process. <i>Leukemia</i> , 2011 , 25, 1408-14	10.7	249
27	Efficacy assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model. <i>Stem Cells and Development</i> , 2011 , 20, 709-19	4.4	18
26	Toll-like receptor-3-activated human mesenchymal stromal cells significantly prolong the survival and function of neutrophils. <i>Stem Cells</i> , 2011 , 29, 1001-11	5.8	153
25	Nestin- and doublecortin-positive cells reside in adult spinal cord meninges and participate in injury-induced parenchymal reaction. <i>Stem Cells</i> , 2011 , 29, 2062-76	5.8	80
24	Quality Controls of Immune Regulatory Properties of Ex-Vivo, GMP-Grade Expanded Mesenchymal Stromal Cells for Clinical Use (European multicenter study CASCADE),. <i>Blood</i> , 2011 , 118, 4049-4049	2.2	
23	Mesenchymal stem cells for clinical application. <i>Vox Sanguinis</i> , 2010 , 98, 93-107	3.1	203
22	Immunological properties of embryonic and adult stem cells. <i>World Journal of Stem Cells</i> , 2010 , 2, 50-60	5.6	34
21	Macrophages may promote cancer growth via a GM-CSF/HB-EGF paracrine loop that is enhanced by CXCL12. <i>Molecular Cancer</i> , 2010 , 9, 273	42.1	79
20	Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide. <i>Stem Cells and Development</i> , 2010 , 19, 1449-70	4.4	254
19	Novel stem/progenitor cells with neuronal differentiation potential reside in the leptomeningeal niche. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 3195-208	5.6	47
18	Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. <i>Stem Cells</i> , 2009 , 27, 2624-35	5.8	323
17	Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. <i>Oncogene</i> , 2008 , 27, 2542-51	9.2	98

16	Stem molecular signature of adipose-derived stromal cells. <i>Experimental Cell Research</i> , 2008 , 314, 603-15	4.2	94
15	Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. <i>Stem Cells</i> , 2008 , 26, 279-89	5.8	380
14	Neuronal differentiation potential of human adipose-derived mesenchymal stem cells. <i>Stem Cells and Development</i> , 2008 , 17, 909-16	4.4	185
13	Immune Modulation by Mesenchymal Stem Cells. <i>Transfusion Medicine and Hemotherapy</i> , 2008 , 35, 194-204	4.4	37
12	Induction of neural-like differentiation in human mesenchymal stem cells derived from bone marrow, fat, spleen and thymus. <i>Bone</i> , 2007 , 40, 382-90	4.7	199
11	Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. <i>Stem Cells and Development</i> , 2007 , 16, 797-810	4.4	100
10	Mesenchymal stem cells: from biology to clinical use. <i>Blood Transfusion</i> , 2007 , 5, 120-9	3.6	67
9	Mesenchymal stem cells for bone, cartilage, tendon and skeletal muscle repair. <i>Bone</i> , 2006 , 39, 678-83	4.7	249
8	Regenerative and immunomodulatory potential of mesenchymal stem cells. <i>Current Opinion in Pharmacology</i> , 2006 , 6, 435-41	5.1	136
7	Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. <i>Stem Cells</i> , 2006 , 24, 386-98	5.8	1030
6	Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia. <i>Haematologica</i> , 2006 , 91, 1109-12	6.6	22
5	HB-EGF/HER-1 signaling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multilineage differentiation. <i>Blood</i> , 2005 , 106, 59-66	2.2	189
4	P53 and p21waf1 Expression by Immunohistochemistry in Diffuse Large B-Cell Lymphoma Has a Strong and Independent Impact on Survival of Patients with Germinal Center Phenotype.. <i>Blood</i> , 2005 , 106, 1920-1920	2.2	
3	Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. <i>Blood</i> , 2003 , 101, 3722-9	2.2	1349
2	Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003 , 120, 74-9	4.5	49
1	Intracellular cytokine profile of cord blood T-, and NK- cells and monocytes. <i>Haematologica</i> , 2000 , 85, 675-9	6.6	40